577.5p 27.5 5.0%
Last Trade - 10:31am
| Market Cap | £114.8m |
| Enterprise Value | £109.1m |
| Revenue | £28.1m |
| Position in Universe | 974th / 1809 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 13.4 | 16.3 | 18.3 | 21.1 | 22.7 | 25.7 | 28.9 | 32.5 | +13.9% | ||
| -66.4 | +107.4 | +4.5 | +36.9 | +100.3 | -28.6 | +118.4 | -1.00 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Instem plc is a supplier of information technology (IT) applications to the early development healthcare market delivering solutions for data collection, management and analysis across the research and development continuum. The Company is engaged in Global Life Sciences operations. Its lead product suite, Provantis, is an application in the Early Development Safety Assessment (EDSA) market. The Provantis solution incorporates a suite of modules required for managing and recording EDSA studies, from receipt of the compound through to the automated assembly of statistical analyses and final reports. Its software allows scientific staff to collect, analyze and share data across the organization and externally. It also offers ALPHADAS, an early phase clinical software solution. The Company offers Centrus suite, which provides pre-built applications, as well as the ability to utilize a range of business intelligence and analysis tools.
| Last Annual | December 31st, 2019 |
| Last Interim | June 30th, 2020 |
| Incorporated | February 5, 2010 |
| Public Since | October 13, 2010 |
| No. of Shareholders: | n/a |
| No. of Employees: | 268 |
| Sector | Technology |
| Industry | Software & IT Services |
| Index | FTSE Aim All Share , |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 20,873,829 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Diamond Way Stone Business Park, STONE, ST15 0SD, United Kingdom |
| Web | http://www.instem.com/ |
| Phone | +44 1785 825600 |
| Contact | () |
| Auditors | RSM UK Audit LLP |
As of 10:31am, shares in Instem are trading at 577.5p, giving the company a market capitalisation of £114.8m. This share price information is delayed by 15 minutes.
Shares in Instem are currently trading at 577.5p and the price has moved by 7.84% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Instem price has moved by 2.41% over the past year.
Of the analysts with advisory recommendations for Instem, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Instem is Not available. You can view the full broker recommendation list by unlocking its StockReport.
Instem is scheduled to issue upcoming financial results on the following dates:
Instem does not currently pay a dividend.
Instem does not currently pay a dividend.
Instem does not currently pay a dividend.
To buy shares in Instem you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Instem are currently trading at 577.5p, giving the company a market capitalisation of £114.8m.
Here are the trading details for Instem:
Based on an overall assessment of its quality, value and momentum, Instem is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We were not able to load any forecast data for Instem.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Instem. Over the past six months, the relative strength of its shares against the market has been -6.32%. At the current price of 577.5p, shares in Instem are trading at 13.12% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Instem PE ratio based on its reported earnings over the past 12 months is 35.19. The shares are currently trading at 577.5p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Instem's management team is headed by:
Here are the top five shareholders of Instem based on the size of their shareholding:
